Zhengxin Group Donates 1.5 Mil Boxes of Masks to Cities in China

On December 10, 2022, Zhengxin Group, a leading personal protective equipment (PPE) manufacturer headquartered in mainland China, announced that they have donated over 1.5 million boxes of masks to various cities within China. The donation aims to help ease the effects of the COVID-19 pandemic following the lifting of lockdowns by the Chinese government in early December.

The new policy in China allows citizens across China to move freely for the first time since the pandemic started in early 2020. However, within the first days of the new policy, new cases surged to over 50,000 per day, causing a massive rise in the demand for face masks.

Zhengxin Group is preparing to donate a warehouse of 1.5 million boxes of masks

“For more than 10 years, Zhengxin has been one of the cooperative suppliers of the Chinese government’s national strategic material reserve, and we are honored to have the opportunity to contribute to the fight against COVID-19, which is our corporate social responsibility,” CEO of Zhengxin Group Danny Peng said. “We have been committed to providing reliable security protection for medical workers around the world, and creating value for our suppliers and employees.”

The mask donation is a manifestation of the performance of Zhengxin Group’s high-efficiency production model through the introduction of fully automated mask production machines in November. Zhengxin will continue to invest in research and development technology to develop high-capacity production equipment to prepare for the next possible virus.

The hightened demand for coverings emptied face masks from pharmacies across the county. In response, Zhengxin Group announced that it will donate 1.5 million boxes of masks from its existing safety stock to various places in China with Beijing, Shanghai and Shenzhen accounting for 45% of the total donations.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”